{"id":"nct:NCT07647614","kind":"trial","title":"A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease","authors":["Energenesis Biomedical Co., Ltd."],"author_count":1,"year":2026,"published":"2026-06-15","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07647614","source_url":"https://clinicaltrials.gov/study/NCT07647614","archive_url":"https://space-kitty.com/papers/nct:NCT07647614","updated":"2026-07-02","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications. The main question it aims to answer is: Does ENERGI-F705 Tablets work to treat Parkinson's disease when used with standard-of-care treatment? Investigators will compare the three treatment groups, high-dose ENERGI-F705 Tablets (120 milligrams twice daily), low-dose ENERGI-F705 Tablets (60 milligrams twice daily), and placebo tablets (a look-alike substance that contains no drug), to see if ENERGI-F705 Tablets work to treat Parkinson's disease. Participants will: * Take the study drugs twice a day for 72 weeks in the treatment group * Take routine use of standard-of-care antiparkinsonian medications throughout the study * Visit the outpatient department at scheduled visits, ranging from Day 1 to approximately every 1 to 4 weeks thereafter, for checkups and tests","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Parkinson's Disease (PD)"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE2","study_type":"INTERVENTIONAL","enrollment":105,"sponsor":"Energenesis Biomedical Co., Ltd.","conditions":["Parkinson's Disease (PD)"],"interventions":["DRUG: 60 milligrams of ENERGI-F705 Tablets","DRUG: Placebo tablets","DRUG: 120 milligrams of ENERGI-F705 Tablets"],"start_date":"2026-12-01","start_date_type":"ESTIMATED","primary_completion_date":"2030-01-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}